BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Target Cut by Wedbush

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price objective dropped by investment analysts at Wedbush from $18.00 to $17.00 in a report released on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Wedbush‘s price objective would suggest a potential upside of 121.07% from the company’s previous close.

BCRX has been the subject of several other research reports. Royal Bank Of Canada cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $13.00 to $11.00 in a research report on Thursday, September 10th. Wall Street Zen upgraded BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, October 24th. JPMorgan Chase & Co. lifted their price objective on BioCryst Pharmaceuticals from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 30th. Weiss Ratings cut BioCryst Pharmaceuticals from a “hold (c)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.38.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock traded up $0.06 during trading hours on Thursday, reaching $7.69. 5,210,856 shares of the company’s stock traded hands, compared to its average volume of 4,880,756. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -5.42 and a beta of 0.55. BioCryst Pharmaceuticals has a fifty-two week low of $6.23 and a fifty-two week high of $11.22. The firm’s 50 day moving average is $8.46 and its 200-day moving average is $8.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. The company had revenue of $180.29 million during the quarter, compared to analysts’ expectations of $165.67 million. During the same quarter in the previous year, the company earned $0.06 EPS. BioCryst Pharmaceuticals’s revenue was up 13.1% on a year-over-year basis. Analysts predict that BioCryst Pharmaceuticals will post -2.28 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC increased its position in shares of BioCryst Pharmaceuticals by 4.6% in the 1st quarter. NewEdge Advisors LLC now owns 52,326 shares of the biotechnology company’s stock valued at $498,000 after buying an additional 2,285 shares in the last quarter. Kestra Advisory Services LLC grew its stake in BioCryst Pharmaceuticals by 20.5% in the first quarter. Kestra Advisory Services LLC now owns 15,740 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 2,680 shares during the period. Nykredit A S acquired a new position in BioCryst Pharmaceuticals in the second quarter valued at about $27,000. Northwestern Mutual Wealth Management Co. grew its stake in BioCryst Pharmaceuticals by 40.2% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 10,254 shares of the biotechnology company’s stock valued at $103,000 after acquiring an additional 2,942 shares during the period. Finally, Winthrop Capital Management LLC bought a new stake in shares of BioCryst Pharmaceuticals in the third quarter worth about $25,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.